全文获取类型
收费全文 | 6940篇 |
免费 | 430篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 160篇 |
妇产科学 | 140篇 |
基础医学 | 1235篇 |
口腔科学 | 198篇 |
临床医学 | 592篇 |
内科学 | 1274篇 |
皮肤病学 | 232篇 |
神经病学 | 905篇 |
特种医学 | 302篇 |
外科学 | 834篇 |
综合类 | 40篇 |
一般理论 | 4篇 |
预防医学 | 338篇 |
眼科学 | 106篇 |
药学 | 528篇 |
中国医学 | 20篇 |
肿瘤学 | 449篇 |
出版年
2023年 | 63篇 |
2022年 | 76篇 |
2021年 | 160篇 |
2020年 | 126篇 |
2019年 | 167篇 |
2018年 | 163篇 |
2017年 | 121篇 |
2016年 | 164篇 |
2015年 | 206篇 |
2014年 | 277篇 |
2013年 | 300篇 |
2012年 | 519篇 |
2011年 | 587篇 |
2010年 | 340篇 |
2009年 | 341篇 |
2008年 | 545篇 |
2007年 | 486篇 |
2006年 | 457篇 |
2005年 | 429篇 |
2004年 | 433篇 |
2003年 | 404篇 |
2002年 | 358篇 |
2001年 | 58篇 |
2000年 | 53篇 |
1999年 | 65篇 |
1998年 | 68篇 |
1997年 | 58篇 |
1996年 | 45篇 |
1995年 | 36篇 |
1994年 | 45篇 |
1993年 | 31篇 |
1992年 | 25篇 |
1991年 | 24篇 |
1990年 | 17篇 |
1989年 | 11篇 |
1988年 | 16篇 |
1987年 | 13篇 |
1986年 | 18篇 |
1985年 | 10篇 |
1984年 | 6篇 |
1983年 | 17篇 |
1982年 | 4篇 |
1981年 | 6篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1976年 | 4篇 |
1971年 | 4篇 |
1969年 | 3篇 |
1968年 | 3篇 |
排序方式: 共有7402条查询结果,搜索用时 15 毫秒
1.
2.
3.
We have shown previously that the plant cannabinoid cannabidiol (CBD) elevates intracellular calcium levels in both cultured hippocampal neurones and glia. Here, we investigated whether the main psychotropic constituent of cannabis, Δ9-tetrahydrocannabinol (THC) alone or in combination with other cannabis constituents can cause similar responses, and whether THC affects the responses induced by CBD. Our experiments were performed with 1 μM pure THC (pTHC), with 1 μM pure CBD (pCBD), with a high-THC, low CBD cannabis extract (eTHC), with a high-CBD, low THC cannabis extract (eCBD), with a mixture of eTHC and eCBD (THC:CBD = 1:1) or with corresponding ‘mock extracts’ that contained only pTHC and pCBD mixed in the same proportion as in eTHC, eCBD or the 1:1 mixture of eTHC and eCBD. 相似文献
4.
Prof. Dr. Alexander Kapp Prof. Dr. Bettina Wedi 《Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete》2006,57(10):854-854
Ohne Zusammenfassung 相似文献
5.
6.
Ernst R. Kuse Joerg Kotzerke Silke Müller Björn Nashan Rainer Lück Karsten Jaeger 《Transplant international》2002,15(6):272-277
It has been demonstrated that total parenteral nutrition (TPN) modulates the function of the hepatic reticuloendothelial system (RES). The objective of this study was to evaluate the impact of two different TPN lipid emulsions on the recovery of allograft RES function after orthotopic liver transplantation (OLTx). In a prospective, double-blind study, OLTx patients were randomly assigned to two treatment groups. Group I ( n=13) received a TPN regimen that included long-chain triglycerides (LCT). Group II ( n=9) received a TPN regimen that included a fat emulsion consisting of both medium-chain triglycerides (MCT) and LCT. At baseline, i.e., on days 2 or 3 after OLTx ( t1), before lipids for TPN were started, hepatic RES function was determined using the human serum albumin millimicrosphere technique (K-value, 1/min). A second measurement ( t2) was obtained after 7 days of TPN, including one of the study's two fat emulsions. The mean (+/- SD) K-value (1/min) was 0.48+/-0.16 in the LCT group and 0.55+/-0.28 in the MCT/LCT group at t1, and it improved to 0.62+/-0.21 in the LCT group and to 0.86+/-0.32 in the MCT/LCT group at t2. RES function recovery was significantly better in the MCT/LCT group ( P< or = 0.05). MCT/LCT emulsion appears to be the TPN fat emulsion of choice after OLTx as it seems to have less impact on hepatic RES recovery. 相似文献
7.
8.
9.
Carlos Iribarren Gail Husson Karsten Sydow Bing-Yin Wang Stephen Sidney John P Cooke 《European journal of cardiovascular prevention and rehabilitation》2007,14(2):222-229
BACKGROUND: Normal endothelial function depends on nitric oxide (NO) release by endothelial cells. Asymmetric dimethylarginine (ADMA), by competing with L-arginine, inhibits NO production and may lead to endothelial dysfunction and atherosclerotic development. Our aim was to ascertain the association between ADMA and coronary artery calcification (CAC), a marker of atherosclerotic coronary disease burden. DESIGN: A nested case-control study within the Coronary Artery Risk Development in Young Adults (CARDIA) cohort, an observational study among young adults residing in four US cities. METHODS: Participants were 263 white and black male and female cases with the presence of CAC and 263 sex and race-matched controls without evidence of CAC by computed tomography, 33-47 years old in 2000-2001. RESULTS: The median level (range) of ADMA was significantly higher in cases (0.55; 0.20-2.22 micromol/l) than in controls (0.53; 0.32-1.30 micromol/l; P=0.03). In conditional logistic regression adjusting for age, field center, educational attainment, smoking status, alcohol consumption, body mass index, waist circumference, hypertension, diabetes, low-density lipoprotein and high-density lipoprotein-cholesterol, triglycerides, renal function and C-reactive protein, the highest tertile of ADMA, compared with the lowest tertile, was associated with 1.80 (95% confidence interval 1.03-3.15) increased odds of the presence of any CAC. By linear regression, a significant independent relationship was also found between ADMA and the degree of CAC. CONCLUSION: These results support a role for ADMA as a biochemical marker of CAC. 相似文献
10.
Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy) 下载免费PDF全文
Rufinamide, a triazole derivative that is structurally distinct from currently marketed antiepileptic drugs (AEDs), is in development for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in children and adults. Rufinamide is well absorbed after oral administration, demonstrates low protein binding, and is metabolized by enzymatic hydrolysis without involvement of cytochrome P450 enzymes, conferring a low drug interaction potential. In a randomized, double-blind trial involving 138 adult and pediatric patients with LGS, compared with placebo, rufinamide 45 mg/kg/day resulted in significantly superior reductions in drop attacks (median change −42.5% vs +1.4% with placebo) and total seizures (−32.1% vs −11.7% with placebo), accompanied by significantly higher responder rates. These results are comparable with findings reported for other AEDs in randomized, controlled clinical trials in patients with LGS. Rufinamide produced statistically significant seizure reduction which was maintained during long-term therapy and accompanied by good tolerability. The most frequently reported adverse events from a pooled safety database evaluating short- and long-term therapy were headache (22.9% and 29.5%), dizziness (15.5% and 22.5%) and fatigue (13.6% and 17.7%). Rufinamide therefore presents a favorable efficacy and tolerability profile and is a promising candidate for the adjunctive therapy of LGS. 相似文献